Brigantine initiates coverage on Avid Technology, Inc. (nasdaq: Avid)
Equities research analysts at Brigantine initiated coverage on shares of Avid Technology, Inc. in a research note to clients and investors on Friday.
Amgen Inc. today announced that the FDA has accepted Amgen's submission and filed a Biologics License Application for denosumab, an investigational RANK Ligand inhibitor